arrow
Y

Yusha Araf

The University of Auckland
H指数:28
被引数:2,768

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Retraction notice to "COVID-19 in Bangladesh: Wave-centric assessments and mitigation measures for future pandemics" [Heliyon 9 (2023) e20113]

撤稿通知:"COVID-19 in Bangladesh: Wave-centric assessments and mitigation measures for future pandemics" [Heliyon 9 (2023) e20113]

Heliyon
IF3.6
2025-12-030
OAAI
Insights into the coinfections of human immunodeficiency virus-hepatitis B virus, human immunodeficiency virus-hepatitis C virus, and hepatitis B virus-hepatitis C virus: prevalence, risk factors, pathogenesis, diagnosis, and treatment (vol 12, 780887, 2022)

洞察人类免疫缺陷病毒-乙型肝炎病毒,人类免疫缺陷病毒-丙型肝炎病毒和乙型肝炎病毒-丙型肝炎病毒的合并感染: 患病率,危险因素,发病机制,诊断和治疗 (vol 12,780887,2022)

2023-08-010
OAAI
Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches

差异基因表达谱揭示了针对SARS-CoV-2的潜在生物标志物和药理化合物: 来自机器学习和生物信息学方法的见解

2022-08-1716
OAAI
Immunoinformatic Design of a Multivalent Peptide Vaccine Against Mucormycosis: Targeting FTR1 Protein of Major Causative Fungi

抗毛霉菌病多价肽疫苗的免疫信息学设计: 靶向主要致病真菌的FTR1蛋白

2022-05-2630
OAAI
Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment

对人类免疫缺陷病毒-乙型肝炎病毒,人类免疫缺陷病毒-丙型肝炎病毒和乙型肝炎病毒-丙型肝炎病毒的合并感染的见解: 患病率,危险因素,发病机制,诊断和治疗

2022-02-0329
OAAI